PriceTargets.com logo

Apnimed - APMD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $50.33
  • Forecasted Upside: 83.36%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$27.45 As of 09/4/2026 05:00 PM ET
▼ -0.36 (-1.29%)

This chart shows the closing price for APMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Apnimed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APMD

Analyst Price Target is $50.33
▲ +83.36% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Apnimed in the last 3 months. The average price target is $50.33, with a high forecast of $60.00 and a low forecast of $41.00. The average price target represents a 83.36% upside from the last price of $27.45.

This chart shows the closing price for APMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in Apnimed.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/13/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/26/2026Zacks ResearchUpgradeHold
8/25/2026EvercoreInitiated CoverageOutperform
8/25/2026Lifesci CapitalInitiated CoverageOutperform$50.00
8/25/2026Bank of AmericaInitiated CoverageBuy$41.00
8/25/2026Cantor FitzgeraldInitiated CoverageOverweight$60.00
(Data available from 9/5/2021 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/6/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/8/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/7/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2026
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2026

Current Sentiment

  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Apnimed logo
Apnimed Inc. is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc. is based in CAMBRIDGE, Mass.
Read More

Today's Range

Now: $27.45
Low: $26.44
High: $28.36

50 Day Range

MA: N/A

52 Week Range

Now: $27.45
Low: $16.12
High: $35.29

Volume

232,872 shs

Average Volume

372,472 shs

Market Capitalization

$763.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Apnimed?

The following equities research analysts have issued reports on Apnimed in the last year: Bank of America Corporation, Cantor Fitzgerald, Evercore Inc, Lifesci Capital, Wall Street Zen, and Zacks Research.
View the latest analyst ratings for APMD.

What is the current price target for Apnimed?

0 Wall Street analysts have set twelve-month price targets for Apnimed in the last year. Their average twelve-month price target is $50.33, suggesting a possible upside of 83.4%. Cantor Fitzgerald has the highest price target set, predicting APMD will reach $60.00 in the next twelve months. Bank of America Corporation has the lowest price target set, forecasting a price of $41.00 for Apnimed in the next year.
View the latest price targets for APMD.

What is the current consensus analyst rating for Apnimed?

Apnimed currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for APMD.